Sign in Sign up for free

Last updated: 7 June 2024 at 5:25pm EST

Jennifer Burstein Net Worth



Ms. Burstein STOK stock SEC Form 4 insiders trading

Jennifer has made over 17 trades of the Stoke Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently she exercised 2,500 units of STOK stock worth $28,375 on 10 December 2018.

The largest trade she's ever made was exercising 2,500 units of Stoke Therapeutics stock on 10 December 2018 worth over $28,375. On average, Jennifer trades about 1,121 units every 17 days since 2015. As of 10 December 2018 she still owns at least 1,250 units of Stoke Therapeutics stock.

You can see the complete history of Ms. Burstein stock trades at the bottom of the page.





Jennifer Burstein biography

Jennifer C. Burstein CPA serves as Independent Director of the Company. From January 2018 to February 2019, Ms. Burstein served as Senior Vice President of Finance and principal financial officer at Loxo Oncology, Inc., a biotechnology company, until its acquisition by Eli Lilly and Company. Ms. Burstein previously served as Vice President of Finance and principal financial officer of Loxo Oncology since May 2015. Prior to Loxo Oncology, Ms. Burstein served as Vice President of Finance at Acorda Therapeutics, Inc., a public biotechnology company, from July 2010 until April 2015, where she held several positions of increasing responsibility in Finance from 2006 until being appointed Vice President of Finance. Prior to joining Acorda, from 2002 to 2006, she was with Eyetech Pharmaceuticals, Inc., a public biotechnology company, which is currently a subsidiary of Valeant Pharmaceuticals International, Inc., where she held several positions of increasing responsibility in Finance until being promoted to Senior Director, Accounting. Before Eyetech, Ms. Burstein worked in the Finance departments at several companies and in public accounting. Ms. Burstein received her B.S. in Business Administration and M.B.A. in Accounting from the State University of New York at Buffalo and has a CPA license in New York.

What is the salary of Jennifer Burstein?

As the Independent Director of Stoke Therapeutics, the total compensation of Jennifer Burstein at Stoke Therapeutics is $511,048. There are 9 executives at Stoke Therapeutics getting paid more, with Stephen Tulipano having the highest compensation of $1,176,400.



How old is Jennifer Burstein?

Jennifer Burstein is 48, she's been the Independent Director of Stoke Therapeutics since 2019. There are 18 older and 1 younger executives at Stoke Therapeutics. The oldest executive at Stoke Therapeutics, Inc. is Dr. Edward M. Kaye M.D., Ph.D., 72, who is the CEO & Director.

What's Jennifer Burstein's mailing address?

Jennifer's mailing address filed with the SEC is C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD, MA, 01730.

Insiders trading at Stoke Therapeutics

Over the last 5 years, insiders at Stoke Therapeutics have traded over $49,612,288 worth of Stoke Therapeutics stock and bought 4,288,550 units worth $94,976,062 . The most active insiders traders include Group, Llc Green Jeremy Red..., Investments, Lpwong Roderic..., and Trust Blue Horizon Enterpri.... On average, Stoke Therapeutics executives and independent directors trade stock every 23 days with the average trade being worth of $1,639,987. The most recent stock trade was executed by Barry Ticho on 3 September 2024, trading 10,000 units of STOK stock currently worth $6,000.



What does Stoke Therapeutics do?

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.



What does Stoke Therapeutics's logo look like?

Stoke Therapeutics, Inc. logo

Stoke Therapeutics executives and stock owners

Stoke Therapeutics executives and other stock owners filed with the SEC include: